brett stringer Search Results


94
Addgene inc lenticrisprv2 hygro
Lenticrisprv2 Hygro, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrisprv2 hygro/product/Addgene inc
Average 94 stars, based on 1 article reviews
lenticrisprv2 hygro - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

98
Addgene inc vector lenticrisprv2
Vector Lenticrisprv2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vector lenticrisprv2/product/Addgene inc
Average 98 stars, based on 1 article reviews
vector lenticrisprv2 - by Bioz Stars, 2026-06
98/100 stars
  Buy from Supplier

90
GenScript corporation lentiviral crispr-cas9 plasmid lenticrispr_v2-puro
Lentiviral Crispr Cas9 Plasmid Lenticrispr V2 Puro, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lentiviral crispr-cas9 plasmid lenticrispr_v2-puro/product/GenScript corporation
Average 90 stars, based on 1 article reviews
lentiviral crispr-cas9 plasmid lenticrispr_v2-puro - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

96
Addgene inc lentiviral particles encoding lrp8 grnas
Schematic depiction of ferroptosis regulators and small molecule modulators. Inhibitors are shown in light blue, and inducers in orange. Analyzis of the depmap portal ( www.depmap.org ) reveals MYCN ‐amplified SK‐N‐DZ as hypersensitive cell lines to the GPX4 inhibitors RSL3 and ML210. Strategy of the genome‐wide CRISPR activation (CRISPRa) screen in MYCN ‐amplified SK‐N‐DZ cells. Overexpression phenotypes conferring resistance to 300 nM RSL3 (left) or 1 μM Erastin (right) treatment. Significant hits are marked in blue (FDR ≤ 0.05), while the highest‐scoring hit, <t>LRP8,</t> is highlighted in red. Overexpression phenotypes conferring resistance to RSL3 (100 nM) induced ferroptosis in the pooled validation CRISPRa screen. Significantly enriched hits (FDR ≤ 0.05) are marked and labeled in blue (known ferroptosis regulators) or red (novel regulators identified in this study). The highest‐scoring hit from the primary screens, LRP8, is highlighted. Strategy of the single‐cell CRISPRa screen to characterize hits from the ferroptosis‐resistance screen. Guide RNA labels are recovered alongside the whole transcriptome readout for each cell. Transcriptomic consequences of CRISPRa of 14 scoring hits from the primary and the validation screens. Each row represents one CRISPRa cluster. For each cluster, the top 50 genes with the most significant differential expression (compared to the nontargeting control cluster) were selected and merged to a signature gene list represented by the columns. Columns and rows were hierarchically clustered based on Pearson's correlation. Source data are available online for this figure.
Lentiviral Particles Encoding Lrp8 Grnas, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lentiviral particles encoding lrp8 grnas/product/Addgene inc
Average 96 stars, based on 1 article reviews
lentiviral particles encoding lrp8 grnas - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

93
Addgene inc lenti sgrna 206 hygro
Schematic depiction of ferroptosis regulators and small molecule modulators. Inhibitors are shown in light blue, and inducers in orange. Analyzis of the depmap portal ( www.depmap.org ) reveals MYCN ‐amplified SK‐N‐DZ as hypersensitive cell lines to the GPX4 inhibitors RSL3 and ML210. Strategy of the genome‐wide CRISPR activation (CRISPRa) screen in MYCN ‐amplified SK‐N‐DZ cells. Overexpression phenotypes conferring resistance to 300 nM RSL3 (left) or 1 μM Erastin (right) treatment. Significant hits are marked in blue (FDR ≤ 0.05), while the highest‐scoring hit, <t>LRP8,</t> is highlighted in red. Overexpression phenotypes conferring resistance to RSL3 (100 nM) induced ferroptosis in the pooled validation CRISPRa screen. Significantly enriched hits (FDR ≤ 0.05) are marked and labeled in blue (known ferroptosis regulators) or red (novel regulators identified in this study). The highest‐scoring hit from the primary screens, LRP8, is highlighted. Strategy of the single‐cell CRISPRa screen to characterize hits from the ferroptosis‐resistance screen. Guide RNA labels are recovered alongside the whole transcriptome readout for each cell. Transcriptomic consequences of CRISPRa of 14 scoring hits from the primary and the validation screens. Each row represents one CRISPRa cluster. For each cluster, the top 50 genes with the most significant differential expression (compared to the nontargeting control cluster) were selected and merged to a signature gene list represented by the columns. Columns and rows were hierarchically clustered based on Pearson's correlation. Source data are available online for this figure.
Lenti Sgrna 206 Hygro, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenti sgrna 206 hygro/product/Addgene inc
Average 93 stars, based on 1 article reviews
lenti sgrna 206 hygro - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

93
Addgene inc pf cag luc hygro plasmid
RK-33 decreases tumor growth rate in a disseminated Burkitt lymphoma xenograft model. (A) Dissemination model. To assess effect of DDX3X inhibition in a dissemination model that mimicks Burkitt lymphoma, NSG mice were i.v. injected with 5 × 10 5 <t>Fluc-CA46-Hygro,</t> 2.5 × 10 5 Fluc-Daudi-Puro or 1 × 10 5 Fluc-Raji-Puro cells. Tumor progression was monitored every other day using an IVIS 200 Xenogen device to detect bioluminescence. Once the average radiance reached the indicated thresholds, mice received six doses of RK-33 over a 2-week period (arrows) while bioluminescent monitoring continued throughout. (B–D) Tumor dissemination progression over time following the initiation of the RK-33 treatment (Day 0 = first injection) in xenografts derived from CA46-Fluc-Hygro (B) , Raji-Fluc-Puro (C) and Daudi-Fluc-Puro (D) cells. Representative RAW bioluminescence images are shown with exposure times of 30 s for Fluc-CA46-Hygro and 1 s exposition for Raji-Fluc-Puro and Daudi-Fluc-Puro xenografts. are shown. * P < 0.05; ** P < 0.01; **** P < 0.0001.
Pf Cag Luc Hygro Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pf cag luc hygro plasmid/product/Addgene inc
Average 93 stars, based on 1 article reviews
pf cag luc hygro plasmid - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

96
Addgene inc plasmid lenticrispr v 2 neo
RK-33 decreases tumor growth rate in a disseminated Burkitt lymphoma xenograft model. (A) Dissemination model. To assess effect of DDX3X inhibition in a dissemination model that mimicks Burkitt lymphoma, NSG mice were i.v. injected with 5 × 10 5 <t>Fluc-CA46-Hygro,</t> 2.5 × 10 5 Fluc-Daudi-Puro or 1 × 10 5 Fluc-Raji-Puro cells. Tumor progression was monitored every other day using an IVIS 200 Xenogen device to detect bioluminescence. Once the average radiance reached the indicated thresholds, mice received six doses of RK-33 over a 2-week period (arrows) while bioluminescent monitoring continued throughout. (B–D) Tumor dissemination progression over time following the initiation of the RK-33 treatment (Day 0 = first injection) in xenografts derived from CA46-Fluc-Hygro (B) , Raji-Fluc-Puro (C) and Daudi-Fluc-Puro (D) cells. Representative RAW bioluminescence images are shown with exposure times of 30 s for Fluc-CA46-Hygro and 1 s exposition for Raji-Fluc-Puro and Daudi-Fluc-Puro xenografts. are shown. * P < 0.05; ** P < 0.01; **** P < 0.0001.
Plasmid Lenticrispr V 2 Neo, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasmid lenticrispr v 2 neo/product/Addgene inc
Average 96 stars, based on 1 article reviews
plasmid lenticrispr v 2 neo - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

93
Addgene inc spcas9 hygro lentiviral vector
RK-33 decreases tumor growth rate in a disseminated Burkitt lymphoma xenograft model. (A) Dissemination model. To assess effect of DDX3X inhibition in a dissemination model that mimicks Burkitt lymphoma, NSG mice were i.v. injected with 5 × 10 5 <t>Fluc-CA46-Hygro,</t> 2.5 × 10 5 Fluc-Daudi-Puro or 1 × 10 5 Fluc-Raji-Puro cells. Tumor progression was monitored every other day using an IVIS 200 Xenogen device to detect bioluminescence. Once the average radiance reached the indicated thresholds, mice received six doses of RK-33 over a 2-week period (arrows) while bioluminescent monitoring continued throughout. (B–D) Tumor dissemination progression over time following the initiation of the RK-33 treatment (Day 0 = first injection) in xenografts derived from CA46-Fluc-Hygro (B) , Raji-Fluc-Puro (C) and Daudi-Fluc-Puro (D) cells. Representative RAW bioluminescence images are shown with exposure times of 30 s for Fluc-CA46-Hygro and 1 s exposition for Raji-Fluc-Puro and Daudi-Fluc-Puro xenografts. are shown. * P < 0.05; ** P < 0.01; **** P < 0.0001.
Spcas9 Hygro Lentiviral Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/spcas9 hygro lentiviral vector/product/Addgene inc
Average 93 stars, based on 1 article reviews
spcas9 hygro lentiviral vector - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

93
Addgene inc lentisgrna neo
RK-33 decreases tumor growth rate in a disseminated Burkitt lymphoma xenograft model. (A) Dissemination model. To assess effect of DDX3X inhibition in a dissemination model that mimicks Burkitt lymphoma, NSG mice were i.v. injected with 5 × 10 5 <t>Fluc-CA46-Hygro,</t> 2.5 × 10 5 Fluc-Daudi-Puro or 1 × 10 5 Fluc-Raji-Puro cells. Tumor progression was monitored every other day using an IVIS 200 Xenogen device to detect bioluminescence. Once the average radiance reached the indicated thresholds, mice received six doses of RK-33 over a 2-week period (arrows) while bioluminescent monitoring continued throughout. (B–D) Tumor dissemination progression over time following the initiation of the RK-33 treatment (Day 0 = first injection) in xenografts derived from CA46-Fluc-Hygro (B) , Raji-Fluc-Puro (C) and Daudi-Fluc-Puro (D) cells. Representative RAW bioluminescence images are shown with exposure times of 30 s for Fluc-CA46-Hygro and 1 s exposition for Raji-Fluc-Puro and Daudi-Fluc-Puro xenografts. are shown. * P < 0.05; ** P < 0.01; **** P < 0.0001.
Lentisgrna Neo, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lentisgrna neo/product/Addgene inc
Average 93 stars, based on 1 article reviews
lentisgrna neo - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

91
Addgene inc lenti spcas9 neo
RK-33 decreases tumor growth rate in a disseminated Burkitt lymphoma xenograft model. (A) Dissemination model. To assess effect of DDX3X inhibition in a dissemination model that mimicks Burkitt lymphoma, NSG mice were i.v. injected with 5 × 10 5 <t>Fluc-CA46-Hygro,</t> 2.5 × 10 5 Fluc-Daudi-Puro or 1 × 10 5 Fluc-Raji-Puro cells. Tumor progression was monitored every other day using an IVIS 200 Xenogen device to detect bioluminescence. Once the average radiance reached the indicated thresholds, mice received six doses of RK-33 over a 2-week period (arrows) while bioluminescent monitoring continued throughout. (B–D) Tumor dissemination progression over time following the initiation of the RK-33 treatment (Day 0 = first injection) in xenografts derived from CA46-Fluc-Hygro (B) , Raji-Fluc-Puro (C) and Daudi-Fluc-Puro (D) cells. Representative RAW bioluminescence images are shown with exposure times of 30 s for Fluc-CA46-Hygro and 1 s exposition for Raji-Fluc-Puro and Daudi-Fluc-Puro xenografts. are shown. * P < 0.05; ** P < 0.01; **** P < 0.0001.
Lenti Spcas9 Neo, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenti spcas9 neo/product/Addgene inc
Average 91 stars, based on 1 article reviews
lenti spcas9 neo - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier

92
Addgene inc brett stringer pcep 4ha b56 alpha addgene
RK-33 decreases tumor growth rate in a disseminated Burkitt lymphoma xenograft model. (A) Dissemination model. To assess effect of DDX3X inhibition in a dissemination model that mimicks Burkitt lymphoma, NSG mice were i.v. injected with 5 × 10 5 <t>Fluc-CA46-Hygro,</t> 2.5 × 10 5 Fluc-Daudi-Puro or 1 × 10 5 Fluc-Raji-Puro cells. Tumor progression was monitored every other day using an IVIS 200 Xenogen device to detect bioluminescence. Once the average radiance reached the indicated thresholds, mice received six doses of RK-33 over a 2-week period (arrows) while bioluminescent monitoring continued throughout. (B–D) Tumor dissemination progression over time following the initiation of the RK-33 treatment (Day 0 = first injection) in xenografts derived from CA46-Fluc-Hygro (B) , Raji-Fluc-Puro (C) and Daudi-Fluc-Puro (D) cells. Representative RAW bioluminescence images are shown with exposure times of 30 s for Fluc-CA46-Hygro and 1 s exposition for Raji-Fluc-Puro and Daudi-Fluc-Puro xenografts. are shown. * P < 0.05; ** P < 0.01; **** P < 0.0001.
Brett Stringer Pcep 4ha B56 Alpha Addgene, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/brett stringer pcep 4ha b56 alpha addgene/product/Addgene inc
Average 92 stars, based on 1 article reviews
brett stringer pcep 4ha b56 alpha addgene - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier

93
Addgene inc lentiviral backbone vector lenti sgrna
RK-33 decreases tumor growth rate in a disseminated Burkitt lymphoma xenograft model. (A) Dissemination model. To assess effect of DDX3X inhibition in a dissemination model that mimicks Burkitt lymphoma, NSG mice were i.v. injected with 5 × 10 5 <t>Fluc-CA46-Hygro,</t> 2.5 × 10 5 Fluc-Daudi-Puro or 1 × 10 5 Fluc-Raji-Puro cells. Tumor progression was monitored every other day using an IVIS 200 Xenogen device to detect bioluminescence. Once the average radiance reached the indicated thresholds, mice received six doses of RK-33 over a 2-week period (arrows) while bioluminescent monitoring continued throughout. (B–D) Tumor dissemination progression over time following the initiation of the RK-33 treatment (Day 0 = first injection) in xenografts derived from CA46-Fluc-Hygro (B) , Raji-Fluc-Puro (C) and Daudi-Fluc-Puro (D) cells. Representative RAW bioluminescence images are shown with exposure times of 30 s for Fluc-CA46-Hygro and 1 s exposition for Raji-Fluc-Puro and Daudi-Fluc-Puro xenografts. are shown. * P < 0.05; ** P < 0.01; **** P < 0.0001.
Lentiviral Backbone Vector Lenti Sgrna, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lentiviral backbone vector lenti sgrna/product/Addgene inc
Average 93 stars, based on 1 article reviews
lentiviral backbone vector lenti sgrna - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

Image Search Results


Schematic depiction of ferroptosis regulators and small molecule modulators. Inhibitors are shown in light blue, and inducers in orange. Analyzis of the depmap portal ( www.depmap.org ) reveals MYCN ‐amplified SK‐N‐DZ as hypersensitive cell lines to the GPX4 inhibitors RSL3 and ML210. Strategy of the genome‐wide CRISPR activation (CRISPRa) screen in MYCN ‐amplified SK‐N‐DZ cells. Overexpression phenotypes conferring resistance to 300 nM RSL3 (left) or 1 μM Erastin (right) treatment. Significant hits are marked in blue (FDR ≤ 0.05), while the highest‐scoring hit, LRP8, is highlighted in red. Overexpression phenotypes conferring resistance to RSL3 (100 nM) induced ferroptosis in the pooled validation CRISPRa screen. Significantly enriched hits (FDR ≤ 0.05) are marked and labeled in blue (known ferroptosis regulators) or red (novel regulators identified in this study). The highest‐scoring hit from the primary screens, LRP8, is highlighted. Strategy of the single‐cell CRISPRa screen to characterize hits from the ferroptosis‐resistance screen. Guide RNA labels are recovered alongside the whole transcriptome readout for each cell. Transcriptomic consequences of CRISPRa of 14 scoring hits from the primary and the validation screens. Each row represents one CRISPRa cluster. For each cluster, the top 50 genes with the most significant differential expression (compared to the nontargeting control cluster) were selected and merged to a signature gene list represented by the columns. Columns and rows were hierarchically clustered based on Pearson's correlation. Source data are available online for this figure.

Journal: EMBO Molecular Medicine

Article Title: LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma

doi: 10.15252/emmm.202318014

Figure Lengend Snippet: Schematic depiction of ferroptosis regulators and small molecule modulators. Inhibitors are shown in light blue, and inducers in orange. Analyzis of the depmap portal ( www.depmap.org ) reveals MYCN ‐amplified SK‐N‐DZ as hypersensitive cell lines to the GPX4 inhibitors RSL3 and ML210. Strategy of the genome‐wide CRISPR activation (CRISPRa) screen in MYCN ‐amplified SK‐N‐DZ cells. Overexpression phenotypes conferring resistance to 300 nM RSL3 (left) or 1 μM Erastin (right) treatment. Significant hits are marked in blue (FDR ≤ 0.05), while the highest‐scoring hit, LRP8, is highlighted in red. Overexpression phenotypes conferring resistance to RSL3 (100 nM) induced ferroptosis in the pooled validation CRISPRa screen. Significantly enriched hits (FDR ≤ 0.05) are marked and labeled in blue (known ferroptosis regulators) or red (novel regulators identified in this study). The highest‐scoring hit from the primary screens, LRP8, is highlighted. Strategy of the single‐cell CRISPRa screen to characterize hits from the ferroptosis‐resistance screen. Guide RNA labels are recovered alongside the whole transcriptome readout for each cell. Transcriptomic consequences of CRISPRa of 14 scoring hits from the primary and the validation screens. Each row represents one CRISPRa cluster. For each cluster, the top 50 genes with the most significant differential expression (compared to the nontargeting control cluster) were selected and merged to a signature gene list represented by the columns. Columns and rows were hierarchically clustered based on Pearson's correlation. Source data are available online for this figure.

Article Snippet: SK‐N‐DZ cells were transduced with lentiviral particles encoding LRP8 gRNAs (lentiCRISPRv2 blast, Addgene plasmid #98293 was a gift from Brett Stringer).

Techniques: Amplification, Genome Wide, CRISPR, Activation Assay, Over Expression, Biomarker Discovery, Labeling, Quantitative Proteomics, Control

Immunoblot analyzis of FLAG and GPX4 in SK‐N‐DZ cells overexpressing an empty vector or hLRP8 ‐Flag. Dose‐dependent toxicity of the ferroptosis inducers Erastin, BSO, and RSL3 in SK‐N‐DZ cell lines stably transduced with a vector expressing hLRP8 ‐Flag. Data are the mean ± SEM of n = 3 wells of a 96‐well plate from three independent experiments. Flow cytometry analyzis of BODIPY 581/591 C11 oxidation in SK‐N‐DZ overexpressing hLRP8 ‐Flag induced by RSL3 treatment (100 nM, 6 h) Data represent the mean ± SEM; n = 3 samples. Statistical analysis was performed using a two‐tailed Student's t ‐test. Heat map depicting the dose‐dependent response of RSL3 in a panel of cell lines overexpressing hLRP8 ‐Flag. Schematic representation of selenium uptake mechanisms. Generation and characterization of LRP8 knockout cell lines using two independent gRNAs. Upper panel, immunoblot analyzis of LRP8 expression in cells transduced with gRNA targeting LRP8 . Lower panel, the viability of cell lines, either wild‐type or knockout for LRP8 in the presence of increasing concentrations of Lip‐1. Data are the mean ± SEM of n = 3 wells of a 96‐well plate from two independent experiments. Recapitulation of LRP8 dependency in the NHO2A cell line derived from a murine model of MYCN amplification. The upper panel depicts the immunoblot of Lrp8 and Gpx4 in cells expressing three independent gRNAs targeting Lrp8 . The lower panel shows the clonogenic capacity of Lrp8‐deficient cells and the protective effect of Lip‐1 (500 nM). Dose‐dependent response of SK‐N‐DZ LRP8 knockout clonal cell line (#2) expressing wild‐type and U46C‐GPX4 in the present of Lip1. Data are the mean ± SEM of n = 3 wells of a 96‐well plate from two independent experiments. The clonogenic capacity of an SK‐N‐DZ LRP8 knockout clonal cell line (#2) expressing wild‐type and U46C‐GPX4. Immunoblot analyzis of FLAG and GPX4 in SK‐N‐DZ cells overexpressing flag‐tagged WT or a U46C variant of GPX4 in wild‐type and knockout LRP8 background. Source data are available online for this figure.

Journal: EMBO Molecular Medicine

Article Title: LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma

doi: 10.15252/emmm.202318014

Figure Lengend Snippet: Immunoblot analyzis of FLAG and GPX4 in SK‐N‐DZ cells overexpressing an empty vector or hLRP8 ‐Flag. Dose‐dependent toxicity of the ferroptosis inducers Erastin, BSO, and RSL3 in SK‐N‐DZ cell lines stably transduced with a vector expressing hLRP8 ‐Flag. Data are the mean ± SEM of n = 3 wells of a 96‐well plate from three independent experiments. Flow cytometry analyzis of BODIPY 581/591 C11 oxidation in SK‐N‐DZ overexpressing hLRP8 ‐Flag induced by RSL3 treatment (100 nM, 6 h) Data represent the mean ± SEM; n = 3 samples. Statistical analysis was performed using a two‐tailed Student's t ‐test. Heat map depicting the dose‐dependent response of RSL3 in a panel of cell lines overexpressing hLRP8 ‐Flag. Schematic representation of selenium uptake mechanisms. Generation and characterization of LRP8 knockout cell lines using two independent gRNAs. Upper panel, immunoblot analyzis of LRP8 expression in cells transduced with gRNA targeting LRP8 . Lower panel, the viability of cell lines, either wild‐type or knockout for LRP8 in the presence of increasing concentrations of Lip‐1. Data are the mean ± SEM of n = 3 wells of a 96‐well plate from two independent experiments. Recapitulation of LRP8 dependency in the NHO2A cell line derived from a murine model of MYCN amplification. The upper panel depicts the immunoblot of Lrp8 and Gpx4 in cells expressing three independent gRNAs targeting Lrp8 . The lower panel shows the clonogenic capacity of Lrp8‐deficient cells and the protective effect of Lip‐1 (500 nM). Dose‐dependent response of SK‐N‐DZ LRP8 knockout clonal cell line (#2) expressing wild‐type and U46C‐GPX4 in the present of Lip1. Data are the mean ± SEM of n = 3 wells of a 96‐well plate from two independent experiments. The clonogenic capacity of an SK‐N‐DZ LRP8 knockout clonal cell line (#2) expressing wild‐type and U46C‐GPX4. Immunoblot analyzis of FLAG and GPX4 in SK‐N‐DZ cells overexpressing flag‐tagged WT or a U46C variant of GPX4 in wild‐type and knockout LRP8 background. Source data are available online for this figure.

Article Snippet: SK‐N‐DZ cells were transduced with lentiviral particles encoding LRP8 gRNAs (lentiCRISPRv2 blast, Addgene plasmid #98293 was a gift from Brett Stringer).

Techniques: Western Blot, Plasmid Preparation, Stable Transfection, Transduction, Expressing, Flow Cytometry, Two Tailed Test, Knock-Out, Derivative Assay, Amplification, Variant Assay

Schematic representation of the SLC‐focused CRISPR knockout screen in the LRP8 wild‐type and LRP8‐deficient cell lines. Results of a CRISPR deletion screen conducted in H1080 and A375 cell lines displayed a log2 fold change between LRP8‐deficient and wild‐type cells. Comparison of SLC7A11 expression in a panel of 23 neuroblastoma cell lines against 1,349 non‐neuroblastoma cell lines demonstrating the lineage‐specific lower expression of SLC7A11 and SLC3A2 ( http://www.depmap.org ). Statistical analysis was performed using an Unpaired t ‐test. **** P < 0.0001. SLC7A11 expression in cancer tissues of different entities. Data retrieved from the R2database . The center line in the box plots indicates the median value. Lower and upper hinges represent the 25 th and 75 th quantiles, the whiskers denote the 1.5× interquartile range, and outliers are marked in the plot. Dot plot depicting the correlation of the dependency of neuroblastoma cell lines on LRP8 and GPX4 (CERES score of −1 means full dependency based on CRISPR–Cas9 knockout screening data) and the expression levels of SLC7A11 in a panel of 27 neuroblastoma cell lines (depmap portal; https://depmap.org/portal/ ). Cell lines with low expression of SLC7A11 were found to be dependent on LRP8 (Pearson correlation r : 0.4858). Schematic representation of system Xc − of selenium uptake mechanisms. The immunoblot of Lrp8, Slc7a11 and Gpx4 in NHO2A stably expressing Cas9 and two independent sgRNAs targeting Lrp8 in an SLC7A11 or mock expressing background and viability of the cell lines in the presence of the DMSO, Lip1 (500 nM), or a combination of both. Cell viability assays depicted are mean ± SD of two independently performed experiments ( n = 4 wells of a 96‐well plate). Generation and characterization of cells overexpressing SLC7A11. Immunoblot analysis of SLC7A11 and SLC3A2 from SK‐N‐DZ cells overexpressing SLC7A11 or mock. Cell competition assay of SK‐N‐DZ cell line overexpressing SLC7A11 or mock controls. For the experiment, cells were seeded at a ratio of 50/50 and 50,000 events were measured via flow cytometry at the depicted time points. Rescue experiments were performed in the presence of 50 μM beta‐Mercaptoethanol (beta‐ME) and 2 μM Erastin. Bars display percentage of eGFP‐ (blue) and Scarlet‐cells (red) with the means ± SD of two independent experiments. Statistical analysis was performed using an Unpaired t ‐test comparing the abundance of SK‐N‐DZ cells overexpressing SLC7A11 (Red). Source data are available online for this figure.

Journal: EMBO Molecular Medicine

Article Title: LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma

doi: 10.15252/emmm.202318014

Figure Lengend Snippet: Schematic representation of the SLC‐focused CRISPR knockout screen in the LRP8 wild‐type and LRP8‐deficient cell lines. Results of a CRISPR deletion screen conducted in H1080 and A375 cell lines displayed a log2 fold change between LRP8‐deficient and wild‐type cells. Comparison of SLC7A11 expression in a panel of 23 neuroblastoma cell lines against 1,349 non‐neuroblastoma cell lines demonstrating the lineage‐specific lower expression of SLC7A11 and SLC3A2 ( http://www.depmap.org ). Statistical analysis was performed using an Unpaired t ‐test. **** P < 0.0001. SLC7A11 expression in cancer tissues of different entities. Data retrieved from the R2database . The center line in the box plots indicates the median value. Lower and upper hinges represent the 25 th and 75 th quantiles, the whiskers denote the 1.5× interquartile range, and outliers are marked in the plot. Dot plot depicting the correlation of the dependency of neuroblastoma cell lines on LRP8 and GPX4 (CERES score of −1 means full dependency based on CRISPR–Cas9 knockout screening data) and the expression levels of SLC7A11 in a panel of 27 neuroblastoma cell lines (depmap portal; https://depmap.org/portal/ ). Cell lines with low expression of SLC7A11 were found to be dependent on LRP8 (Pearson correlation r : 0.4858). Schematic representation of system Xc − of selenium uptake mechanisms. The immunoblot of Lrp8, Slc7a11 and Gpx4 in NHO2A stably expressing Cas9 and two independent sgRNAs targeting Lrp8 in an SLC7A11 or mock expressing background and viability of the cell lines in the presence of the DMSO, Lip1 (500 nM), or a combination of both. Cell viability assays depicted are mean ± SD of two independently performed experiments ( n = 4 wells of a 96‐well plate). Generation and characterization of cells overexpressing SLC7A11. Immunoblot analysis of SLC7A11 and SLC3A2 from SK‐N‐DZ cells overexpressing SLC7A11 or mock. Cell competition assay of SK‐N‐DZ cell line overexpressing SLC7A11 or mock controls. For the experiment, cells were seeded at a ratio of 50/50 and 50,000 events were measured via flow cytometry at the depicted time points. Rescue experiments were performed in the presence of 50 μM beta‐Mercaptoethanol (beta‐ME) and 2 μM Erastin. Bars display percentage of eGFP‐ (blue) and Scarlet‐cells (red) with the means ± SD of two independent experiments. Statistical analysis was performed using an Unpaired t ‐test comparing the abundance of SK‐N‐DZ cells overexpressing SLC7A11 (Red). Source data are available online for this figure.

Article Snippet: SK‐N‐DZ cells were transduced with lentiviral particles encoding LRP8 gRNAs (lentiCRISPRv2 blast, Addgene plasmid #98293 was a gift from Brett Stringer).

Techniques: CRISPR, Knock-Out, Comparison, Expressing, Western Blot, Stable Transfection, Competitive Binding Assay, Flow Cytometry

Schematic representation of the orthotopic implantation of control (LRP8 WT ) or LRP8‐deficient (LRP8 KO ) SK‐N‐DZ cell lines. Kaplan–Meier plot displaying tumor‐free survival (TFS) for mice injected orthotopically with LRP8 WT (red, n = 9) or LRP8 KO (blue, n = 9) SK‐N‐DZ cells. A Gehan–Breslow–Wilcoxon test was conducted for statistical analyzis. Tumor growth upon orthotopic implantation of LRP8 WT (red, n = 9) or LRP8 KO (blue, n = 9) of SK‐N‐DZ cell line. Data represent the mean ± SEM; Mann–Whitney test one‐tailed P ‐values are indicated. Representative luminescence images from each group are sown in (C). Outline of the orthotopic implantation and treatment scheme with Liproxstatin‐1 (Lip‐1) of LRP8 WT and LRP8 KO SK‐N‐DZ cells. Tumor weight of orthotopically implanted LRP8 WT (red, n = 9) or LRP8 KO (blue and yellow, n = 9 each) SK‐N‐DZ cells. All mice were treated with Lip‐1 for 5 days. After this, treatment was ceased for LRP8 WT (red) and LRP8 KO cohorts (blue) or maintained for an additional 14 days (yellow); see for details. Tumors were analyzed at the endpoint. The center line in the box plots indicates the median value. Lower and upper hinges represent the 25 th and 75 th quantiles, the whiskers denote the Max and Min value. Mann–Whitney test one‐tailed P values are indicated. Representative images of tumors in the control (red) and LRP8 KO groups (blue) treated with Lip‐1 for 5 days after implantation. Immunoblot analyzis of LRP8 and GPX4 levels from orthotopic tumors of LRP8 WT or LRP8 KO SK‐N‐DZ cells, treated with Lip‐1 for 5 days after implantation, followed by 14 days after randomization. Schematic representation for the proposed model of LRP8 inhibition essentiality. Comparison of selenium /selenocysteine uptake mechanisms via LRP8 and system Xc − in proliferating MYCN‐amplified cells, depicting the contribution of primarily LRP8/SELENOP supporting selenoprotein translation (left panel). Inhibition of LRP8 in system Xc − low cell selectively triggers ferroptosis in MYCN ‐amplified neuroblastoma (right panel). SELENOP, Selenoprotein P; iSe, inorganic selenium; SeCys, Selenocysteine. Source data are available online for this figure.

Journal: EMBO Molecular Medicine

Article Title: LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma

doi: 10.15252/emmm.202318014

Figure Lengend Snippet: Schematic representation of the orthotopic implantation of control (LRP8 WT ) or LRP8‐deficient (LRP8 KO ) SK‐N‐DZ cell lines. Kaplan–Meier plot displaying tumor‐free survival (TFS) for mice injected orthotopically with LRP8 WT (red, n = 9) or LRP8 KO (blue, n = 9) SK‐N‐DZ cells. A Gehan–Breslow–Wilcoxon test was conducted for statistical analyzis. Tumor growth upon orthotopic implantation of LRP8 WT (red, n = 9) or LRP8 KO (blue, n = 9) of SK‐N‐DZ cell line. Data represent the mean ± SEM; Mann–Whitney test one‐tailed P ‐values are indicated. Representative luminescence images from each group are sown in (C). Outline of the orthotopic implantation and treatment scheme with Liproxstatin‐1 (Lip‐1) of LRP8 WT and LRP8 KO SK‐N‐DZ cells. Tumor weight of orthotopically implanted LRP8 WT (red, n = 9) or LRP8 KO (blue and yellow, n = 9 each) SK‐N‐DZ cells. All mice were treated with Lip‐1 for 5 days. After this, treatment was ceased for LRP8 WT (red) and LRP8 KO cohorts (blue) or maintained for an additional 14 days (yellow); see for details. Tumors were analyzed at the endpoint. The center line in the box plots indicates the median value. Lower and upper hinges represent the 25 th and 75 th quantiles, the whiskers denote the Max and Min value. Mann–Whitney test one‐tailed P values are indicated. Representative images of tumors in the control (red) and LRP8 KO groups (blue) treated with Lip‐1 for 5 days after implantation. Immunoblot analyzis of LRP8 and GPX4 levels from orthotopic tumors of LRP8 WT or LRP8 KO SK‐N‐DZ cells, treated with Lip‐1 for 5 days after implantation, followed by 14 days after randomization. Schematic representation for the proposed model of LRP8 inhibition essentiality. Comparison of selenium /selenocysteine uptake mechanisms via LRP8 and system Xc − in proliferating MYCN‐amplified cells, depicting the contribution of primarily LRP8/SELENOP supporting selenoprotein translation (left panel). Inhibition of LRP8 in system Xc − low cell selectively triggers ferroptosis in MYCN ‐amplified neuroblastoma (right panel). SELENOP, Selenoprotein P; iSe, inorganic selenium; SeCys, Selenocysteine. Source data are available online for this figure.

Article Snippet: SK‐N‐DZ cells were transduced with lentiviral particles encoding LRP8 gRNAs (lentiCRISPRv2 blast, Addgene plasmid #98293 was a gift from Brett Stringer).

Techniques: Control, Injection, MANN-WHITNEY, One-tailed Test, Western Blot, Inhibition, Comparison, Amplification

Oligonucleotides used for cloning of individual  gRNAs.

Journal: EMBO Molecular Medicine

Article Title: LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma

doi: 10.15252/emmm.202318014

Figure Lengend Snippet: Oligonucleotides used for cloning of individual gRNAs.

Article Snippet: SK‐N‐DZ cells were transduced with lentiviral particles encoding LRP8 gRNAs (lentiCRISPRv2 blast, Addgene plasmid #98293 was a gift from Brett Stringer).

Techniques: Cloning, Sequencing

RK-33 decreases tumor growth rate in a disseminated Burkitt lymphoma xenograft model. (A) Dissemination model. To assess effect of DDX3X inhibition in a dissemination model that mimicks Burkitt lymphoma, NSG mice were i.v. injected with 5 × 10 5 Fluc-CA46-Hygro, 2.5 × 10 5 Fluc-Daudi-Puro or 1 × 10 5 Fluc-Raji-Puro cells. Tumor progression was monitored every other day using an IVIS 200 Xenogen device to detect bioluminescence. Once the average radiance reached the indicated thresholds, mice received six doses of RK-33 over a 2-week period (arrows) while bioluminescent monitoring continued throughout. (B–D) Tumor dissemination progression over time following the initiation of the RK-33 treatment (Day 0 = first injection) in xenografts derived from CA46-Fluc-Hygro (B) , Raji-Fluc-Puro (C) and Daudi-Fluc-Puro (D) cells. Representative RAW bioluminescence images are shown with exposure times of 30 s for Fluc-CA46-Hygro and 1 s exposition for Raji-Fluc-Puro and Daudi-Fluc-Puro xenografts. are shown. * P < 0.05; ** P < 0.01; **** P < 0.0001.

Journal: Frontiers in Cell and Developmental Biology

Article Title: Inhibiting the RNA helicase DDX3X in Burkitt lymphoma induces oxydative stress and impedes tumor progression in xenografts

doi: 10.3389/fcell.2025.1642006

Figure Lengend Snippet: RK-33 decreases tumor growth rate in a disseminated Burkitt lymphoma xenograft model. (A) Dissemination model. To assess effect of DDX3X inhibition in a dissemination model that mimicks Burkitt lymphoma, NSG mice were i.v. injected with 5 × 10 5 Fluc-CA46-Hygro, 2.5 × 10 5 Fluc-Daudi-Puro or 1 × 10 5 Fluc-Raji-Puro cells. Tumor progression was monitored every other day using an IVIS 200 Xenogen device to detect bioluminescence. Once the average radiance reached the indicated thresholds, mice received six doses of RK-33 over a 2-week period (arrows) while bioluminescent monitoring continued throughout. (B–D) Tumor dissemination progression over time following the initiation of the RK-33 treatment (Day 0 = first injection) in xenografts derived from CA46-Fluc-Hygro (B) , Raji-Fluc-Puro (C) and Daudi-Fluc-Puro (D) cells. Representative RAW bioluminescence images are shown with exposure times of 30 s for Fluc-CA46-Hygro and 1 s exposition for Raji-Fluc-Puro and Daudi-Fluc-Puro xenografts. are shown. * P < 0.05; ** P < 0.01; **** P < 0.0001.

Article Snippet: To establish a luciferase-expressing CA46 cell line, parental CA46 cells were transfected with the pF CAG luc hygro plasmid (a gift from Brett Stringer; Addgene plasmid #67502; http://n2t.net/addgene:67502 ; RRID: Addgene_67502).

Techniques: Inhibition, Injection, Derivative Assay